The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead.
Negar Hosseinkhani,Afshin Derakhshani,Mahdi Abdoli Shadbad,Antonella Argentiero,Vito Racanelli,Tohid Kazemi,Ahad Mokhtarzadeh,Oronzo Brunetti,Nicola Silvestris,Behzad Baradaran +9 more
Reads0
Chats0
TLDR
Wang et al. as mentioned in this paper reviewed the current evidence about the structure and expression pattern of VISTA, its role in TME, the clinicopathological significance, and its prognostic values in various cancers and proposed a strategy to overcome tumor immune-resistance states.Abstract:
Immune checkpoints (ICs) have pivotal roles in regulating immune responses. The inhibitory ICs in the tumor microenvironment (TME) have been implicated in the immune evasion of tumoral cells. Therefore, identifying and targeting these inhibitory ICs might be critical for eliminating tumoral cells. V-domain immunoglobulin suppressor of T cell activation (VISTA) is a novel inhibitory IC that is expressed on myeloid cells, lymphoid cells, and tumoral cells; therefore, VISTA can substantially regulate innate and adaptive anti-tumoral immune responses. Besides, growing evidence indicates that VISTA blockade can enhance the sensitivity of tumoral cells to conventional IC-based immunotherapy, e.g., cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors. In this regard, the current study aimed to review the current evidence about the structure and expression pattern of VISTA, its role in TME, the clinicopathological significance of VISTA, and its prognostic values in various cancers. Besides, this review intended to collect the lessons from the recent pre-clinical and clinical studies and propose a strategy to overcome tumor immune-resistance states.read more
Citations
More filters
Journal ArticleDOI
Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects.
Shima Makaremi,Zahra Asadzadeh,Nima Hemmat,Amir Baghbanzadeh,Alessandro Sgambato,Farid Ghorbaninezhad,Hossein Safarpour,Antonella Argentiero,Oronzo Brunetti,Renato Bernardini,Nicola Silvestris,Behzad Baradaran +11 more
TL;DR: In this article, a review summarizes recent advances in immune checkpoint inhibitors (ICIs), such as CTLA-4, PD-1, PDL1, LAG-3, and TIM-3 in colorectal cancer (CRC) treatment.
Journal ArticleDOI
Dendritic cell-based cancer immunotherapy in the era of immune checkpoint inhibitors: From bench to bedside.
Farid Ghorbaninezhad,Zahra Asadzadeh,Javad Masoumi,Ahad Mokhtarzadeh,Tohid Kazemi,Leili Aghebati-Maleki,Siamak Sandoghchian Shotorbani,Mahdi Abdoli Shadbad,Amir Baghbanzadeh,Nima Hemmat,Mohammad Bakhshivand,Behzad Baradaran +11 more
TL;DR: In this paper , the authors reviewed the biology of Dendritic cells in developing T-cell-mediated anti-tumoral immune responses, the significance of immunoregulatory cells in the tumor microenvironment, metabolic barriers contributing to DCs dysfunction in the TME, tumor-derived immunosuppressive factors, and inhibitory immune checkpoint molecules in DC-based cell therapy outcomes.
Journal ArticleDOI
A scoping review on the potentiality of PD-L1-inhibiting microRNAs in treating colorectal cancer: Toward single-cell sequencing-guided biocompatible-based delivery
Mahdi Abdoli Shadbad,Zahra Asadzadeh,Afshin Derakhshani,Negar Hosseinkhani,Ahad Mokhtarzadeh,Amir Baghbanzadeh,Khalil Hajiasgharzadeh,Oronzo Brunetti,Antonella Argentiero,Vito Racanelli,Nicola Silvestris,Behzad Baradaran +11 more
TL;DR: In this paper, a scoping review aimed to discuss the currently available evidence regarding the therapeutic potentiality of PD-L1-inhibiting microRNAs for colorectal cancer.
Journal ArticleDOI
Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
TL;DR: In this paper, the authors reviewed the role of immune checkpoint inhibitors in clinical therapy of cancer and other diseases, and discussed the correlation between immune checkpoints and microorganisms and the role in microbial-infection diseases.
Journal ArticleDOI
Immune Checkpoint Inhibitors for Vaccine Improvements: Current Status and New Approaches
Alexander Batista-Duharte,Fakhri Hassouneh,Pablo Álvarez-Heredia,Alejandra Pera,Rafael Solana +4 more
TL;DR: The current state and future directions of the use of ICIs in experimental and clinical settings, including mAbs and alternative new approaches using antisense oligonucleotides (ASOs), small non-coding RNAs, aptamers, peptides, and other small molecules for improving vaccine efficacy are reviewed.
References
More filters
Journal ArticleDOI
The blockade of immune checkpoints in cancer immunotherapy
TL;DR: Preliminary clinical findings with blockers of additional immune-checkpoint proteins, such as programmed cell death protein 1 (PD1), indicate broad and diverse opportunities to enhance antitumour immunity with the potential to produce durable clinical responses.
Journal ArticleDOI
Immunity, Inflammation, and Cancer
TL;DR: The principal mechanisms that govern the effects of inflammation and immunity on tumor development are outlined and attractive new targets for cancer therapy and prevention are discussed.
Journal ArticleDOI
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Jérôme Galon,Anne Costes,Fátima Sánchez-Cabo,Amos Kirilovsky,Bernhard Mlecnik,Christine Lagorce-Pagès,Marie Tosolini,Matthieu Camus,Anne Berger,Philippe Wind,Franck Zinzindohoué,Patrick Bruneval,Paul-Henri Cugnenc,Zlatko Trajanoski,Wolf H. Fridman,Franck Pagès +15 more
TL;DR: In situ analysis of tumor-infiltrating immune cells may be a valuable prognostic tool in the treatment of colorectal cancer and possibly other malignancies.
Journal ArticleDOI
The future of immune checkpoint therapy
Padmanee Sharma,James P. Allison +1 more
TL;DR: The way forward for this class of novel agents lies in the ability to understand human immune responses in the tumor microenvironment, which will provide valuable information regarding the dynamic nature of the immune response and regulation of additional pathways that will need to be targeted through combination therapies to provide survival benefit for greater numbers of patients.
Journal ArticleDOI
CTLA-4 can function as a negative regulator of T cell activation
Theresa L. Walunas,Deborah J. Lenschow,Christina Y. Bakker,Peter S. Linsley,Gordon J. Freeman,Jonathan Green,Craig B. Thompson,Craig B. Thompson,Jeffrey A. Bluestone +8 more
TL;DR: Results suggest that the MAb may obstruct the interaction of CTLA-4 with its natural ligand and block a negative signal, or directly signal T cells to down-regulate immune function.